A new study has shown how trained human coders were able to identify observable markers of therapeutic connection during psilocybin administration in psychedelic-assisted therapy.
atai Life Sciences has announced results from its Phase 1 Study of DMX-1002 (Ibogaine) for the treatment of opioid use disorder (OUD).
Researchers at Lund University have developed a new measuring technique to understand what happens to the neurons in rats’ brains when they are given psychedelics.
Marking a world first, researchers at Imperial’s Centre for Psychedelic Research will investigate psilocybin as a treatment for gambling addiction with the support of funding from...
A new Phase 1 study looking at psilocybin in combination with psychological support as a treatment for females with anorexia nervosa has shown positive results.
The final cohort of patients has been dosed in Cybin’s Dosing Phase 2 Trial investigating CYB003 – an investigational deuterated analogue of psilocybin – as a...
Kernel has published results from its Cybin-sponsored neuroimaging study which show the ability of Kernel’s Flow1 system to capture and analyse brain changes induced by psychedelics.
A low-cost version of ketamine has shown promising results in its treatment of resistant depression in a double-blind trial.
A donation of $1.5 million has been gifted to the UC San Diego Psychedelics and Health Research Initiative to research DMT by philanthropist Eugene Jhong.
Until now, it has been commonly thought that selective serotonin reuptake inhibitors (SSRIs) could interfere with the therapeutic potential of psilocybin treatment.